SCHEMBL20847640

SCHEMBL20847640

CC(C)N(Cc1ccc(F)cc1F)S(=O)(=O)c1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 5/20 0.48
HDAC8 Q9BY41 4/20 0.48
HDAC11 Q96DB2 2/20 0.48
HDAC3 O15379 1/20 0.48
CA2 P00918 1/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
RIPK1 Q13546 2/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
HDAC2 Q92769 1/20 0.39
BMP1 P13497 1/20 0.38
TAS2R14 Q9NYV8 1/20 0.38
NR3C1 P04150 1/20 0.36
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20847653 0.82 HDAC8 (0.50) HDAC6HDAC8HDAC11HDAC3CA2
SCHEMBL20847508 0.81 HDAC6 (0.48) HDAC6HDAC8HDAC11HDAC3CA2
SCHEMBL20847659 0.79 HDAC6 (0.67) HDAC6HDAC8HDAC11HDAC3HDAC2
SCHEMBL20847608 0.78 HDAC8 (0.39) HDAC6HDAC8HDAC11HDAC3CA2
SCHEMBL20847470 0.75 HDAC6 (0.50) HDAC6HDAC8HDAC11HDAC3SLC6A2
SCHEMBL23793202 0.75 BMP1 (0.44) HDAC6HDAC8HDAC11HDAC3CA2
SCHEMBL20847790 0.74 RORC (0.53) HDAC6HDAC8HDAC11HDAC3
SCHEMBL20847618 0.70 CA2 (0.45) HDAC6HDAC8HDAC11HDAC3CA2
SCHEMBL22909579 0.70 MAOB (0.43)
SCHEMBL23793201 0.70 CA2 (0.41) HDAC6HDAC8HDAC11HDAC3CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200277268-A1 PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF DALRIADA THERAPEUTICS INC. (CA) 2020-09-03 US disclosed
WO-2019056120-A1 PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF DALRIADA THERAPEUTICS INC. (CA) 2019-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200277268-A1 PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF MKI67, PKD1, ETV6 HDAC6 499/4885HDAC8 1916/4885HDAC11 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.